{"id":"W4399010918","doi":"10.1038/s41591-024-03043-1","title":"IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Dialysis and Renal Disease Management","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; University of Toronto; University of Alberta","funders":"National Heart, Lung, and Blood Institute; American Regent; CytoSorbents Europe; CSL Limited; LG Chem; Idorsia Pharmaceuticals; Jewish General Hospital; Novo Nordisk; Canada Excellence Research Chairs, Government of Canada; Fondation Leducq; Horizon Therapeutics; Galderma; ReCor Medical; Sanofi; Abiomed; Ionis Pharmaceuticals; Zogenix; National Institutes of Health; Regeneron Pharmaceuticals; Boston Scientific Corporation; CSL Behring; Cleveland Clinic; Bristol-Myers Squibb; Eli Lilly and Company; Amarin Corporation; AstraZeneca; AtriCure; Duke Clinical Research Institute; Astellas Pharma; Cytokinetics; University of Toronto; Alexion Pharmaceuticals; Esperion Therapeutics; Alnylam Pharmaceuticals; Daiichi Sankyo Europe; Servier; Gilead Sciences; Kowa Company; Amgen; HLS Therapeutics; LivaNova; York University; Pfizer","keywords":"Medicine; Randomized controlled trial; Dialysis; Internal medicine; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00132619,0.0002761584,0.001119278,0.0006763742,0.00003965128,0.00003274105,0.00007102271,0.0002008698,0.0002551464],"category_scores_gemma":[0.001089118,0.0001449285,0.0002387571,0.001131583,0.0001924433,0.0001089511,0.00003357243,0.0007674722,0.00002131771],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001899101,"about_ca_system_score_gemma":0.00009093175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003501632,"about_ca_topic_score_gemma":0.00003271453,"domain_scores_codex":[0.9974388,0.0001968795,0.0006369331,0.0005203055,0.000893614,0.0003134857],"domain_scores_gemma":[0.9989945,0.0002371548,0.0001239785,0.0003046506,0.0001577059,0.0001820223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9222618,0.001407537,0.0002297244,0.000606937,0.0009077241,0.0008890853,0.0009429331,0.000009440422,0.0001942615,0.001608366,0.01888529,0.05205695],"study_design_scores_gemma":[0.9763609,0.00181735,0.00139873,0.005249114,0.00217218,0.000005824313,0.0001406056,0.001157091,0.00009100579,0.0003279397,0.01106763,0.0002116736],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9642478,0.004454617,0.0007985128,0.01081175,0.001483643,0.003708587,0.00001588403,0.0001799595,0.01429922],"genre_scores_gemma":[0.9953743,0.0003687068,0.0001283213,0.001512795,0.001021489,0.0001979269,0.0003637826,0.00003594773,0.0009967056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05409911,"threshold_uncertainty_score":0.5910013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006076207528880322,"score_gpt":0.2808173565854118,"score_spread":0.2747411490565315,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}